Atreca, Inc. BCEL

Full chart Compare
Set alert

Price alert · BCEL

All alert types
0.09 +0.09

Day range unavailable

52-week range unavailable

Discussion (14)

Sign in to join the discussion

VICKY HANUKA BCEL 3 years ago #6

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi

-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.

VICKY HANUKA BCEL 3 years ago #8

Merge is happening October 9 don’t miss it